Sign in
CompletedNo phase

Steriwave ICU Pilot Study

Key facts

Who runs it
Fraser Health
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
227 people enrolled
Started
18 Mar 2025
Ended
31 Dec 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Antimicrobial photodynamic therapy (aPDT) nasal decolonization device
Record updated
5 March 2026

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • All ICU patients 19 years and above
  • Expected length of ICU stay >48 hrs

Who cannot take part

  • Allergy to methylene blue and/or chlorhexidine gluconate, or unknown allergy status
  • Pregnant/breastfeeding individuals
  • Nasal or facial trauma that limits access to the nose
  • Inability for the patients to tolerate or comply with treatment, as determined by their treating physician
  • Patient, TSDM or MRP declines participation
  • Co-enrolment with other research studies will be considered in an individual basis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a single-center, non-blinded, prospective, pilot study enrolling patients admitted to the critical care unit at Royal Columbian Hospital. This study investigates the effects of universal nasal decolonization using antimicrobial photodynamic therapy (aPDT) on the prevention of hospital-acquired pneumonia (HAP), ventilator-acquired pneumonia (VAP), and hospital-acquired bloodstream infection (BSI) in this patient population.

Read full original descriptionShow less

Main Objectives include:

* To determine whether a large, multi-center RCT of this protocol is feasible * To determine baseline rates of VAP, HAP, and ICU-acquired BSI * To gather preliminary efficacy data regarding VAP, HAP, and ICU-acquired BSI prevention using universal aPDT nasal decolonization * To gather preliminary microbiological data on the effect of universal aPDT procedures on nasal carriage of various microoganisms in ICU patients.

The 2 groups in the trial

  • Control ArmNo study treatment, for comparison

    The first two months will constitute the control period before the aPDT intervention is introduced into the unit. No nasal decolonization procedures (current standard of care) will take place at this time. All patients enrolled in the study will receive a nasal swab upon ICU admission, and once every four days during their stay.

  • Intervention ArmTreatment being tested

    Nasal decolonization procedures will be administered every other day. Just as during the intervention period, a nasal swab will be administered every four days to assess the microbiology of the nose prior to the scheduled nasal decontamination treatment

    Treatment: Antimicrobial photodynamic therapy (aPDT) nasal decolonization device

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
5 March 2026